Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 5/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.33 |
| ▸ | NNMT | P40261 | 13/20 | 0.33 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22685145 | 0.90 | NNMT (0.34) | PRMT5WDR77NNMT | |
| SCHEMBL20049423 | 0.89 | PRMT5 (0.37) | PRMT5WDR77NNMTFGFR1FGFR4 | |
| SCHEMBL19344195 | 0.89 | PRMT5 (0.37) | PRMT5WDR77NNMTFGFR1FGFR4 | |
| SCHEMBL24067676 | 0.86 | NNMT (0.32) | PRMT5WDR77NNMTPIP4K2A | |
| SCHEMBL22002065 | 0.81 | NNMT (0.36) | PRMT5WDR77NNMT | |
| SCHEMBL21312932 | 0.74 | NNMT (0.33) | NNMT | |
| SCHEMBL22002059 | 0.73 | PRMT5 (0.39) | PRMT5WDR77 | |
| SCHEMBL18572246 | 0.73 | PRMT5 (0.37) | PRMT5WDR77 | |
| SCHEMBL24067749 | 0.72 | PRMT5 (0.38) | PRMT5WDR77 | |
| SCHEMBL21312896 | 0.71 | PRMT5 (0.36) | PRMT5WDR77NNMTFGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198699-B2 | Compounds targeting PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20190263833-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263833-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT8 | PRMT5 1/4885WDR77 94/4885NNMT 52/4885 |
| US-11198699-B2 | Compounds targeting PRMT5 | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 49/4885NNMT 656/4885 |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 49/4885NNMT 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.